Skip to content

Esketamine Combined with Ropivacaine for Transversus Abdominis Plane Block: Effects on Postoperative Analgesia and Postpartum Depression after Cesarean Section

Esketamine Combined with Ropivacaine for Transversus Abdominis Plane Block: Effects on Postoperative Analgesia and Postpartum Depression after Cesarean Section

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600129121
Enrollment
Unknown
Registered
2026-07-31
Start date
2024-12-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum depression and post-operative pain in patients with cesarean section

Interventions

Trial Group:0.125 mg/kg esketamine combined with hydrochloric acid ropivacaine 100 mg diluted to total volume 40 ml for ultrasound-guided bilateral TAP block.
Control Group:Hydrochloric acid ropivacaine 100 mg diluted to total volume of 40 ml and performed bilateral TAP block under ultrasound guidance.

Sponsors

Linyi Maternal and Child Health Care Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Age must be =18 years old and =45 years old; 2. Singleton term pregnancy; 3. Scheduled elective cesarean delivery; 4. ASA physical status I–III; 5. Able to understand and complete EPDS and VAS assessments; 6. Preoperative EPDS score <9 points; 7. Willing to participate and sign written informed consent.

Exclusion criteria

Exclusion criteria: 1. Allergy to esketamine, ketamine, ropivacaine, or other amide local anesthetics; 2. Severe hepatic, renal, or cardiac dysfunction; 3. Uncontrolled hypertensive disorders of pregnancy; 4. History of psychiatric disorders, or current use of antidepressants, antipsychotics, or sedative-hypnotics; 5. Chronic pain or long-term opioid use; 6. Contraindications to TAP block or neuraxial anesthesia; 7. Conversion to general anesthesia during surgery; 8. Serious perioperative complications

Design outcomes

Primary

MeasureTime frame
EPDS score on postpartum day 30;

Secondary

MeasureTime frame
EPDS score on preoperative day 1 ;EPDS score on postoperative day ; EPDS score on postoperative day 4;6h post-operative VAS pain score;12h post-operative VAS pain score;24h post-operative VAS pain score;48h post-operative VAS pain score;6h post-operative number of PCIA boluses;12h post-operative number of PCIA boluses;24h post-operative number of PCIA boluses;48h post-operative number of PCIA boluses;Remedies for pain relief at 6h after surgery (50mg of tramadol, daily total amount not exceeding 400mg);Remedies for pain relief at 12h after surgery (50mg of tramadol, daily total amount not exceeding 400mg);Remedies for pain relief at 24h after surgery (50mg of tramadol, daily total amount not exceeding 400mg);Remedies for pain relief at 48h after surgery (50mg of tramadol, daily total amount not exceeding 400mg);Adverse reactions 6 hours after surgery: including nausea, vomiting, dizziness, itchy skin, nightmares;Adverse reactions 12 hours after surgery: including nausea, vomiting, dizziness, itchy skin, nightmares;Adverse reactions 24 hours after surgery: including nausea, vomiting, dizziness, itchy skin, nightmares;Adverse reactions 48 hours after surgery: including nausea, vomiting, dizziness, itchy skin, nightmares;

Countries

China

Contacts

Public ContactChen Bin

Linyi Maternal and Child Health Care Hospital

335196065@qq.com+86 138 8489 1802

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026